HUP0302632A2 - Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt - Google Patents
Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alattInfo
- Publication number
- HUP0302632A2 HUP0302632A2 HU0302632A HUP0302632A HUP0302632A2 HU P0302632 A2 HUP0302632 A2 HU P0302632A2 HU 0302632 A HU0302632 A HU 0302632A HU P0302632 A HUP0302632 A HU P0302632A HU P0302632 A2 HUP0302632 A2 HU P0302632A2
- Authority
- HU
- Hungary
- Prior art keywords
- antigestagens
- maturation during
- infertility treatment
- endometrial maturation
- during infertility
- Prior art date
Links
- 230000002357 endometrial effect Effects 0.000 title abstract 2
- 230000036512 infertility Effects 0.000 title abstract 2
- 208000000509 infertility Diseases 0.000 title abstract 2
- 231100000535 infertility Toxicity 0.000 title abstract 2
- 230000035800 maturation Effects 0.000 title abstract 2
- 239000003418 antiprogestin Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003146 progesterones Chemical class 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75628601A | 2001-01-09 | 2001-01-09 | |
| US09/801,925 US20020143000A1 (en) | 2001-01-09 | 2001-03-09 | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
| PCT/IB2002/001764 WO2002067910A2 (en) | 2001-01-09 | 2002-01-09 | The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0302632A2 true HUP0302632A2 (hu) | 2003-11-28 |
Family
ID=27116200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302632A HUP0302632A2 (hu) | 2001-01-09 | 2002-01-09 | Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040152684A1 (enExample) |
| EP (1) | EP1365765B1 (enExample) |
| JP (1) | JP2004520411A (enExample) |
| CN (1) | CN1244329C (enExample) |
| AR (1) | AR032390A1 (enExample) |
| AT (1) | ATE367817T1 (enExample) |
| AU (1) | AU2002253488B2 (enExample) |
| BG (1) | BG107977A (enExample) |
| BR (1) | BR0206367A (enExample) |
| CA (1) | CA2433776A1 (enExample) |
| CZ (1) | CZ20031864A3 (enExample) |
| DE (1) | DE60221359T2 (enExample) |
| DK (1) | DK1365765T3 (enExample) |
| EE (1) | EE200300321A (enExample) |
| ES (1) | ES2290284T3 (enExample) |
| HR (1) | HRP20030628A2 (enExample) |
| HU (1) | HUP0302632A2 (enExample) |
| IL (1) | IL156729A0 (enExample) |
| MX (1) | MXPA03006156A (enExample) |
| NO (1) | NO20033125L (enExample) |
| NZ (1) | NZ526908A (enExample) |
| PL (1) | PL361689A1 (enExample) |
| SK (1) | SK8612003A3 (enExample) |
| WO (1) | WO2002067910A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009034362A1 (de) * | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) * | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) * | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| US20130029953A1 (en) * | 2011-07-28 | 2013-01-31 | Klaus Nickisch | Progesterone antagonists |
| EP3501533B1 (en) * | 2014-12-22 | 2025-07-09 | Ferring B.V. | Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies |
| EP3214092A1 (en) | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3533175A1 (de) * | 1985-09-13 | 1987-03-19 | Schering Ag | Antigestagene zur verschiebung der endometrialen reifung |
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| DE19860719A1 (de) * | 1998-12-23 | 2000-06-29 | Schering Ag | Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen |
-
2002
- 2002-01-09 EE EEP200300321A patent/EE200300321A/xx unknown
- 2002-01-09 NZ NZ526908A patent/NZ526908A/en unknown
- 2002-01-09 CN CNB028061462A patent/CN1244329C/zh not_active Expired - Fee Related
- 2002-01-09 CA CA002433776A patent/CA2433776A1/en not_active Abandoned
- 2002-01-09 JP JP2002567278A patent/JP2004520411A/ja active Pending
- 2002-01-09 EP EP02722637A patent/EP1365765B1/en not_active Expired - Lifetime
- 2002-01-09 DE DE60221359T patent/DE60221359T2/de not_active Expired - Fee Related
- 2002-01-09 CZ CZ20031864A patent/CZ20031864A3/cs unknown
- 2002-01-09 DK DK02722637T patent/DK1365765T3/da active
- 2002-01-09 ES ES02722637T patent/ES2290284T3/es not_active Expired - Lifetime
- 2002-01-09 SK SK861-2003A patent/SK8612003A3/sk unknown
- 2002-01-09 BR BR0206367-0A patent/BR0206367A/pt not_active IP Right Cessation
- 2002-01-09 HU HU0302632A patent/HUP0302632A2/hu unknown
- 2002-01-09 PL PL36168902A patent/PL361689A1/xx not_active Application Discontinuation
- 2002-01-09 HR HR20030628A patent/HRP20030628A2/hr not_active Application Discontinuation
- 2002-01-09 AT AT02722637T patent/ATE367817T1/de not_active IP Right Cessation
- 2002-01-09 IL IL15672902A patent/IL156729A0/xx unknown
- 2002-01-09 AU AU2002253488A patent/AU2002253488B2/en not_active Ceased
- 2002-01-09 AR ARP020100053A patent/AR032390A1/es unknown
- 2002-01-09 MX MXPA03006156A patent/MXPA03006156A/es unknown
- 2002-01-09 WO PCT/IB2002/001764 patent/WO2002067910A2/en not_active Ceased
-
2003
- 2003-07-08 BG BG107977A patent/BG107977A/bg unknown
- 2003-07-08 NO NO20033125A patent/NO20033125L/no not_active Application Discontinuation
- 2003-12-30 US US10/747,060 patent/US20040152684A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040152684A1 (en) | 2004-08-05 |
| ES2290284T3 (es) | 2008-02-16 |
| BR0206367A (pt) | 2003-12-23 |
| BG107977A (bg) | 2004-08-31 |
| IL156729A0 (en) | 2004-02-08 |
| NO20033125L (no) | 2003-09-09 |
| HK1065953A1 (en) | 2005-03-11 |
| WO2002067910A2 (en) | 2002-09-06 |
| ATE367817T1 (de) | 2007-08-15 |
| CZ20031864A3 (en) | 2004-03-17 |
| DK1365765T3 (da) | 2007-10-29 |
| DE60221359D1 (de) | 2007-09-06 |
| WO2002067910A3 (en) | 2003-02-06 |
| NZ526908A (en) | 2005-07-29 |
| CA2433776A1 (en) | 2002-09-06 |
| EP1365765A2 (en) | 2003-12-03 |
| EP1365765B1 (en) | 2007-07-25 |
| DE60221359T2 (de) | 2008-04-17 |
| CN1496263A (zh) | 2004-05-12 |
| NO20033125D0 (no) | 2003-07-08 |
| HRP20030628A2 (en) | 2005-06-30 |
| SK8612003A3 (en) | 2004-03-02 |
| PL361689A1 (en) | 2004-10-04 |
| AU2002253488B2 (en) | 2007-02-15 |
| EE200300321A (et) | 2003-10-15 |
| AR032390A1 (es) | 2003-11-05 |
| JP2004520411A (ja) | 2004-07-08 |
| MXPA03006156A (es) | 2003-09-16 |
| CN1244329C (zh) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20001744D0 (no) | Fremgangsmåter for å behandle psykose forbundet med glykokortikoidrelatert dysfunksjon | |
| IL145838A0 (en) | Methods of assessing, improving, urogenital health in postmenopausal women | |
| IL161581A0 (en) | Pyrazolidinone derivatives and their use | |
| EP1118323A3 (en) | Method of reducing morbidity and the risk of mortality | |
| MY130681A (en) | Compositions and methods for treating female sexual dysfunction | |
| NO20072518L (no) | Kjonns stereoid forloper alene eller i kombinasjon med en selektiv ostrogen reseptor modulator og /eller med ostrogener og /eller en type 5 CGMP fosfodiesteraseinhibitor for a forebygge eller behandle vaginal torrhet og seksuell dysfunksjon hos postmenopausale kvinner. | |
| MXPA06014798A (es) | Antagonistas del receptor de hormona para liberar gonadotropina. | |
| MXPA02001306A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. | |
| MEP6408A (xx) | Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću | |
| ATE424209T1 (de) | Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung | |
| ATE529116T1 (de) | Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect) | |
| HUP0302632A2 (hu) | Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt | |
| IL163937A (en) | Contrast agents for magnetic resonance imaging and methods related thereto | |
| WO2006106311A3 (en) | Combination treatment methods for treating sex-hormone dependent disease and fertility treatment | |
| IL162602A (en) | Pyrrolidine derivatives as prostaglandin modulators | |
| MA30901B1 (fr) | Therapie de combinaison sequentielle | |
| MXPA04002389A (es) | Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico. | |
| WO2002056903A3 (en) | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators | |
| EA200300750A1 (ru) | Применение антигестагенов для ингибирования ускоренного созревания эндометрия в процессе лечения бесплодия | |
| MXPA05008347A (es) | Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis. | |
| HUP0203050A2 (hu) | Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények | |
| WO2003015872A3 (en) | Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders | |
| TR200100240T2 (tr) | Anksiyete bozukluklarının tedavisi | |
| MA27152A1 (fr) | Association d'un inhibiteur de pde4 selectif et d'un agoniste de recepteur beta-2 adrenergique | |
| UY27115A1 (es) | Uso de gestágenos para inhibir la maduración acelerada del endometrio durante el tratamiento de la infertilidad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |